Free Trial

Gibraltar Capital Management Inc. Purchases 20,833 Shares of Merck & Co., Inc. (NYSE:MRK)

Merck & Co., Inc. logo with Medical background

Gibraltar Capital Management Inc. grew its position in shares of Merck & Co., Inc. (NYSE:MRK - Free Report) by 35.5% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 79,551 shares of the company's stock after purchasing an additional 20,833 shares during the period. Merck & Co., Inc. comprises about 1.5% of Gibraltar Capital Management Inc.'s holdings, making the stock its 23rd largest holding. Gibraltar Capital Management Inc.'s holdings in Merck & Co., Inc. were worth $7,141,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently modified their holdings of MRK. Barnes Dennig Private Wealth Management LLC bought a new stake in shares of Merck & Co., Inc. in the 1st quarter valued at about $27,000. WealthTrak Capital Management LLC bought a new stake in shares of Merck & Co., Inc. in the 4th quarter valued at about $35,000. MorganRosel Wealth Management LLC bought a new stake in shares of Merck & Co., Inc. in the 1st quarter valued at about $36,000. Spurstone Advisory Services LLC bought a new stake in shares of Merck & Co., Inc. in the 4th quarter valued at about $37,000. Finally, Hurley Capital LLC bought a new stake in shares of Merck & Co., Inc. in the 4th quarter valued at about $40,000. Institutional investors own 76.07% of the company's stock.

Insiders Place Their Bets

In other Merck & Co., Inc. news, SVP Dalton E. Smart III sold 4,262 shares of Merck & Co., Inc. stock in a transaction on Friday, April 25th. The stock was sold at an average price of $82.76, for a total value of $352,723.12. Following the completion of the sale, the senior vice president owned 7,778 shares of the company's stock, valued at approximately $643,707.28. This trade represents a 35.40% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 0.09% of the stock is currently owned by company insiders.

Merck & Co., Inc. Stock Up 3.2%

MRK stock traded up $2.59 on Wednesday, reaching $83.96. 9,249,444 shares of the company traded hands, compared to its average volume of 16,240,312. Merck & Co., Inc. has a one year low of $73.31 and a one year high of $129.93. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.41 and a quick ratio of 1.16. The company has a market cap of $210.84 billion, a P/E ratio of 12.22, a price-to-earnings-growth ratio of 0.84 and a beta of 0.39. The firm has a fifty day simple moving average of $79.09 and a 200-day simple moving average of $86.73.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last posted its quarterly earnings data on Thursday, April 24th. The company reported $2.22 earnings per share for the quarter, beating analysts' consensus estimates of $2.16 by $0.06. Merck & Co., Inc. had a return on equity of 43.23% and a net margin of 27.27%. The company had revenue of $15.53 billion during the quarter, compared to analyst estimates of $15.59 billion. During the same quarter last year, the company earned $2.07 EPS. The firm's revenue for the quarter was down 1.6% on a year-over-year basis. Research analysts anticipate that Merck & Co., Inc. will post 9.01 earnings per share for the current year.

Merck & Co., Inc. Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, July 8th. Investors of record on Monday, June 16th were given a dividend of $0.81 per share. This represents a $3.24 dividend on an annualized basis and a yield of 3.86%. The ex-dividend date of this dividend was Monday, June 16th. Merck & Co., Inc.'s dividend payout ratio (DPR) is presently 47.16%.

Analysts Set New Price Targets

MRK has been the subject of a number of recent research reports. Cantor Fitzgerald lowered Merck & Co., Inc. from an "overweight" rating to a "cautious" rating in a research note on Tuesday, May 20th. Citigroup reiterated a "neutral" rating and issued a $84.00 price objective (down previously from $115.00) on shares of Merck & Co., Inc. in a report on Wednesday, May 14th. Wall Street Zen cut Merck & Co., Inc. from a "strong-buy" rating to a "buy" rating in a report on Friday, April 25th. Finally, Guggenheim reiterated a "buy" rating and issued a $115.00 price objective on shares of Merck & Co., Inc. in a report on Thursday, April 17th. One research analyst has rated the stock with a sell rating, twelve have assigned a hold rating, seven have issued a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of "Hold" and an average target price of $109.19.

Get Our Latest Report on Merck & Co., Inc.

Merck & Co., Inc. Company Profile

(Free Report)

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.

Further Reading

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Should You Invest $1,000 in Merck & Co., Inc. Right Now?

Before you consider Merck & Co., Inc., you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Merck & Co., Inc. wasn't on the list.

While Merck & Co., Inc. currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Don’t Miss These Top 3 Defense Stocks Set To Gain
Triple-Digit Gains: These 4 Nuclear Stocks Have Even More Upside Ahead
3 Made in America Stocks Under $20 You Need to See!

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines